Obesity Linked to Worse Patient-Reported Outcomes in Rheumatoid Arthritis
HCPLive
JUNE 29, 2024
Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.
Behavioral Strategies to Conquer Obesity in Clinical Care
Cardiometabolic Health Congress
FEBRUARY 10, 2025
Obesity is a complex, chronic condition that significantly impacts cardiometabolic health and overall well-being. 1 Dietary Modifications: Evidence-Based Approaches Low-Fat vs. Low-Carb Diets A meta-analysis of 48 randomized controlled trials (RCTs) revealed no significant difference in weight loss outcomes between low-fat and low-carb diets.
Obesity 
52
52 
Good Response to Obesity Treatment in Childhood Improved Outcomes Down the Line
Med Page Today
JANUARY 21, 2025
(MedPage Today) -- Beneficial pediatric obesity treatment response was associated with a reduced risk of obesity-related events in young adults, a nationwide prospective cohort study in Sweden showed. Compared with poor response, good response.
Obesity 92
92 
How You Can Reduce The Risk Of Heart Disease Without Losing Weight.
Dr. Paddy Barrett
NOVEMBER 15, 2024
A study of almost 10,000 adults with obesity (BMI >30) who were evaluated for all LE8 factors and followed for over 7 years can give us some insight 1. The study found that the higher/better a person’s LE8 score was, the less likely each of these three outcomes was to occur. Can we take the obesity risk off the table also?
SUMMIT: No Impact From Baseline eGFR on HF Outcomes With Tirzepatide
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
Tirzepatide Reduces Heart Failure Outcomes in Obesity-Related Heart Failure
HCPLive
AUGUST 1, 2024
Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.
Case report of belt electrode-skeletal muscle electrical stimulation for acute heart failure with severe obesity: a novel therapeutic option for acute phase rehabilitation
Frontiers in Cardiovascular Medicine
MARCH 7, 2024
Background Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. B-SES could be an option for patients with heart failure who have limited mobility and obesity.
Heart Failure 124
124 
SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
Have We Turned The Tide On Obesity?
Dr. Paddy Barrett
OCTOBER 11, 2024
Obesity is one of the world’s biggest health crisis and only seems to be getting worse. For over 50 years, the rates of obesity have continued to rise worldwide 1. The most recent data on obesity has shown a decline for the first time in a very long time. Between 2020 and 2023, the rates of obesity dropped by about 2% 2.
Obesity 81
81 
Popular diabetes and obesity drugs also protect kidneys, study shows
Science Daily - Heart Disease
NOVEMBER 25, 2024
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.
Diabetes 118
118 
The Potential Risks of GLP-1s
CardiacWire
JANUARY 22, 2025
Starting with the good news, GLP-1s lowered risks for 42 health outcomes while increasing risks for 19 outcomes. Its also worth noting that the data came from military veterans who were older and mainly white, so the outcomes might not apply to other populations. year follow-up.
Obesity 59
59 
Obesity and acute type A aortic dissection: unraveling surgical outcomes through the lens of the upper hemisternotomy approach
Frontiers in Cardiovascular Medicine
JANUARY 31, 2024
Obesity, a pervasive health concern, has been identified as a significant risk factor for ATAAD, introducing unique surgical challenges that can influence postoperative outcomes. Based on BMI (WS/T 428-2013), patients were categorized into normal weight, overweight, and obese. Results The average age of the cohort was 50.1 ± 11.2
Obesity 64
64 
ACCEL Lite: The Evolving Therapeutic Landscape in Obesity and the Effect on CV Outcomes
American College of Cardiology
MARCH 25, 2025
Richard Chazal and Mikhail Kosiborod explore the rapidly evolving therapeutic landscape of obesity, with a particular focus on the cardiovascular benefits of emerging treatments. In this interview, Drs.
Obesity 56
56 
Semaglutide in Obesity-Related HFpEF: Pooled Analysis
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
NAFLD Presents Similar Risk for Adverse Outcomes Regardless of BMI
HCPLive
JANUARY 5, 2024
Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.
BMI 105
105 
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be Presented at ACC.24
DAIC
MARCH 26, 2024
milla1cf Tue, 03/26/2024 - 13:00 March 26, 2024 — Esperion announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen ) Outcomes subgroup analyses as poster presentations at th e 2024 American College of Cardiology’s Annual Scientific Session ( ACC.24 24 ) in Atlanta, Georgia.
Outcomes 105
105 
Obesity worsens outcomes of right ventricular dysfunction: Insights from a hospital-based study
Cardiology Update
DECEMBER 11, 2023
Previous studies have associated obesity with negative changes in the right ventricle using imaging techniques. However, the connection between obesity and more direct measures of right ventricle function, particularly those reflecting hemodynamic consequences, have been unclear. Original article: Circ Heart Fail. 2023;16:e010524.
Obesity 52
52 
Cost-effectiveness of Polypills, Obesity and FH, Adverse Pregnancy Outcomes and Long-term HF Risk
American College of Cardiology
JANUARY 29, 2025
He then discusses overweight and obesity in patients with familial hyperlipidemia. In this weeks View, Dr. Eagle examines the cost-effectiveness of polypills.
Obesity 58
58 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
American College of Cardiology
DECEMBER 14, 2023
The goal of the SELECT trial was to determine the association of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with cardiovascular (CV) events in a secondary prevention cohort of patients with overweight or obesity and prior CV disease (CVD) without diabetes mellitus (DM).
Obesity 56
56 
Semaglutide Improves Outcomes in Patients with Obesity, HFpEF, and Type 2 Diabetes
NEJM Journal Watch - Cardiology
APRIL 7, 2024
In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.
Obesity 74
74 
Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing
Frontiers in Cardiovascular Medicine
FEBRUARY 10, 2025
Furthermore, we highlight how recent trends in prescription of GLP-1 receptor antagonists are serving to motivate patients to manage biomarkers related to T2D and obesity, which are also relevant in cardiovascular disease.
GLP-1s and heart outcomes: 5 recent findings
Becker's Hospital Review - Cardiology
DECEMBER 2, 2024
With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and Zepbound can address outcomes in cardiovascular health.
Outcomes 64
64 
Rivus HU6 Shows Obesity-HFpEF Potential
CardiacWire
AUGUST 14, 2024
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements – without the risk of muscle loss. The post Rivus HU6 Shows Obesity-HFpEF Potential appeared first on Cardiac Wire.
Obesity 52
52 
Winning the Battle Against Atherosclerosis: Practical, Proactive Solutions
Cardiometabolic Health Congress
JANUARY 16, 2025
Precision Medicine: Personalizing Prevention for Better Outcomes Precision medicine provides tools to customize prevention and treatment plans based on individual risk factors. Precision medicine, primordial prevention, and addressing systemic barriers can improve outcomes and reduce the burden of CVD globally.
Is the obesity paradox in outpatients with heart failure reduced ejection fraction real?
Frontiers in Cardiovascular Medicine
DECEMBER 13, 2023
Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF). group provided the worst outcome ( p = 0.123). Results BMI 30–34.9 and BMI 18.5–24.9 had the best prognosis, BMI 25–29.9 group ( p = 0.033).
Outpatient 59
59 
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
European Journal of Heart Failure
OCTOBER 9, 2024
Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. However, previous studies suggest the effects on heart failure outcomes vary according to left ventricular ejection fraction (LVEF). Obesity did not modify the effects of EQW on HHF.
Diabetes 75
75 
PO-06-026 OUTCOMES IN NON-OBESE HEART FAILURE PATIENTS WITH METABOLIC SYNDROME OR DIABETES
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction
Circulation: Heart Failure
OCTOBER 27, 2023
The role of obesity in RV dysfunction and adverse outcomes is unclear.METHODS:We examined patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. BACKGROUND:Right ventricular (RV) dysfunction is associated with increased mortality across a spectrum of cardiovascular diseases.
Obesity 40
40 
Tirzepatide Improves HFpEF Symptoms and Outcomes
CardiacWire
AUGUST 2, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.
Outcomes 59
59 
Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD
Cardiometabolic Health Congress
JULY 25, 2023
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Obesity 52
52 
Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis
Journal of the American Heart Association
FEBRUARY 8, 2025
This analysis evaluated the efficacy and safety of bempedoic acid in people with obesity participating in the CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACLInhibiting Regimen) Outcomes trial.MethodsCLEAR Outcomes randomized 13 970 patients to daily bempedoic acid 180 mg or placebo. and hsCRP of 23.2%
Obesity 40
40 
Association of body composition with left ventricular remodeling and outcomes in diabetic heart failure with reduced ejection fraction: assessment of sarcopenic obesity using cardiac MRI
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
No Plaque, No Problem: Tackling Atherosclerosis Prevention
Cardiometabolic Health Congress
JANUARY 15, 2025
This imbalance is partly due to limited healthcare access, fewer preventive resources, and challenges in addressing risk factors such as obesity and diabetes. For example, the global spread of obesity, particularly among youth, has set the stage for a future pandemic of non-communicable diseases.
The role of body composition in left ventricular remodeling, reverse remodeling, and clinical outcomes for heart failure with mildly reduced ejection fraction: more knowledge to the “obesity paradox”
Cardiovascular Diabetology
SEPTEMBER 10, 2024
Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.
Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options
Journal of the American Heart Association
DECEMBER 29, 2023
Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration.
Obesity 45
45 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
The New England Journal of Medicine
NOVEMBER 10, 2023
In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
Obesity 40
40 
Abstract 4112652: Impact of metabolic overweight/obesity phenotypes on clinical outcomes of patients with resectable non-small cell lung cancer in an Asian population
Circulation
NOVEMBER 11, 2024
Background:Metabolic syndrome and obesity are known to increase the incidence of lung cancer. We investigated the association between metabolic health and overweight/obesity phenotypes and clinical outcomes in patients with resectable non-small cell lung cancer (NSCLC).Methods:This 0.96, p = 0.022).Conclusions:After
Obesity 40
40 
Circadian disruption, clock genes, and metabolic health
Journal of Clinical Investigation - Cardiology
JULY 15, 2024
These circadian mechanisms represent potential pathophysiological pathways linking circadian disruption to adverse metabolic health outcomes, including obesity, metabolic syndrome, and type 2 diabetes.
Diabetes 111
111 
Revolutionary Results: How Modern Weight Loss Medications are Changing the Game
Dr. Paddy Barrett
DECEMBER 12, 2023
That’s what the field of obesity therapeutics feels like right now. Low levels of muscle mass are associated with a range of adverse outcomes, and a therapy that causes this would not be a good long-term health strategy. Subscribe now 1 [link] 2 [link] 3 Retatrutide Phase 2 Obesity Trial Investigators. N Engl J Med.
Obesity 105
105 
One year clinical and safety outcome of obese patients undergoing pulmonary vein isolation for atrial fibrillation with pulsed field ablation or cryoballoon ablation - a propensity matched analysis
HeartRhythm
APRIL 3, 2025
Thermal-based ablation techniques, such as cryoballoon ablation (CBA), are widely used for pulmonary vein isolation (PVI) but show notable recurrence rates, particularly in obese patients.
Ablation 40
40 
Heart disease in pregnancy and risk of pre-eclampsia: a Swedish register-based study
Open Heart
MAY 23, 2024
Background and aims Pre-eclampsia complicates 3–5% of pregnancies worldwide and is associated with adverse outcomes for the mother and the offspring. Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia.
Heart Disease and Stroke Could Affect at Least 60% of Adults in U.S. by 2050, According to American Heart Association Advisories
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8
Heart Disease 105
105 Abstract 4144999: Cardiac Magnetic Resonance Imaging in Tetrology of Fallot Patients and Relationship to Obesity
Circulation
NOVEMBER 11, 2024
Obesity is associated with increased cardiovascular risk and adverse cardiac changes such as left ventricular hypertrophy (LVH) and in TOF higher body mass index (BMI) contributed to increase risk. In the presence of obesity, RVEDVi may underestimate the severity of RV volume load. mL/m2, p=0.04; RVEDVi 157.4±21.5 vs RVEDV 297.6±56.6
Obesity 40
40 
Let's personalize your content